2025-07-22 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc (TMDX) based on the provided data, formatted as a report in English.

## Transmedics Group Inc (TMDX) Analysis

Transmedics Group Inc is a medical technology company pioneering a novel approach to preserve donor organs for transplantation.

### 1. Performance Relative to S&P 500 (VOO)

*   **TMDX Cumulative Return:** 223.19%
*   **VOO (S&P 500) Cumulative Return:** 68.64%
*   **Absolute Divergence:** 159.6
*   **Relative Divergence:** 62.1 (This indicates that TMDX's performance is in the 62.1 percentile range of its historical divergence from the S&P 500.)

**Analysis:** TMDX has significantly outperformed the S&P 500 over the analyzed period. The relative divergence suggests the current outperformance is within its historical range, but still leaning towards the higher end.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta | Cap(B) |
|------------|---------|--------|---------|------|--------|
| 2019-2021  | -4.0%  | 63.4%  | -52.0% | 0.0  | 0.7   |
| 2020-2022  | 140.0% | 68.3%  | 138.0% | 0.1  | 2.1   |
| 2021-2023  | 95.0%  | 69.4%  | 77.0%  | 0.2  | 2.7   |
| 2022-2024  | 147.0% | 82.8%  | 121.0% | 0.2  | 2.1   |
| 2023-2025  | 104.0% | 82.8%  | 55.0%  | 0.5  | 3.5   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows strong growth in recent periods (2020-2025), indicating significant investment returns over the past few years.
*   **MDD:** The Maximum Drawdown (MDD) is relatively high, particularly in 2022-2025, indicating substantial risk.
*   **Alpha:** The high positive alpha values for 2020-2025 suggest that TMDX has consistently outperformed its benchmark.
*   **Beta:** The beta values, which range from 0.0 to 3.5, indicate varying levels of volatility relative to the market.
*   **Cap(B):** Market capitalization has increased from 0.7B to 3.5B, showing increased investor confidence.

### 2. Recent Price Action

*   **Current Price:** 103.61
*   **Last Market Data:** price: 103.61, previousClose: 109.88, change: -5.71
*   **5-day Moving Average:** 111.00
*   **20-day Moving Average:** 122.76
*   **60-day Moving Average:** 120.17

**Analysis:** The stock price has recently declined, closing at 103.61 with a significant drop of -5.71 from the previous close. The price is currently below all three moving averages (5-day, 20-day, and 60-day), suggesting a short-term downtrend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3383 (Low Risk)
*   **RSI (Relative Strength Index):** 18.63 (Oversold)
*   **PPO (Percentage Price Oscillator):** -2.12
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35)
*   **Delta_Previous_Relative_Divergence:** -0.9 (Negative change indicates short-term decline)
*   **Expected Return:** 59.6% (Projected excess return over S&P 500 with long-term investment)

**Analysis:**

*   The low RSI value suggests the stock may be oversold and potentially poised for a rebound.
*   The negative PPO reinforces the short-term bearish trend.
*   The "Hybrid Signal" suggests a cautious approach, recommending selling a small portion of holdings and maintaining a high cash ratio due to market uncertainty (MRI: 0.35).
*   The negative change in relative divergence (-0.9) confirms the recent underperformance relative to the S&P 500.
*   Despite the short-term bearish signals, the high expected return (59.6%) indicates significant long-term potential compared to the S&P 500.

### 4. Recent News & Significant Events

*   **[2025-07-19]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-21]:** Analysts discussing performance and outlook in the context of industry trends and global economic factors.
*   **[2025-07-20]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-18]:** Market experts highlight both risks and opportunities, advising monitoring recent news and company announcements.

**Analysis:** Recent news suggests TMDX is experiencing heightened volatility and is subject to significant market attention due to business developments, regulatory changes, or market events. Investors should closely monitor news and announcements.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 예상 EPS |
|------------|------|---------|
| 2025-05-08 | 0.7  | 0.29   |
| 2025-02-27 | 0.19 | 0.22   |
| 2024-10-28 | 0.12 | 0.29   |
| 2024-07-31 | 0.35 | 0.21   |
| 2024-04-30 | 0.35 | 0.03256 |

**Analysis:** The company has consistently beaten EPS estimates, particularly in the most recent quarter (2025-05-08). This indicates strong earnings performance and positive business momentum. However, a few quarters show EPS below expectations, which could be a source of concern.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |
| 2024-03-31 | $0.10B  | 61.91%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-03-31 | $0.27B  | 9.64%  |
| 2024-12-31 | $0.23B  | 3.00%  |
| 2024-09-30 | $0.21B  | 2.01%  |
| 2024-06-30 | $0.19B  | 6.42%  |
| 2024-03-31 | $0.16B  | 7.65%  |

**Analysis:**

*   **Revenue:** Revenue has consistently increased over the past five quarters, indicating strong business growth.
*   **Profit Margin:** The profit margin is very high, consistently above 55%, which suggests efficient operations and strong pricing power.
*   **Equity:** Total equity has also increased consistently, reflecting the company's strong financial position.
*   **ROE (Return on Equity):** ROE shows some fluctuation but has significantly increased in the latest quarter, indicating improved profitability and efficient use of equity.

### 7. Overall Analysis

Transmedics Group Inc (TMDX) has demonstrated strong growth, outperforming the S&P 500 significantly. Recent data highlights a short-term downtrend, possibly influenced by recent news and volatility. However, the company's strong earnings performance, high profit margins, and positive revenue growth suggest long-term potential.

**Key Takeaways:**

*   **Short-Term Caution:** Technical indicators suggest caution in the short term due to the recent price decline and oversold conditions.
*   **Long-Term Growth:** Strong fundamentals, including increasing revenue, high profit margins, and consistent EPS beats, indicate a positive long-term outlook.
*   **Monitor News:** Given the recent volatility and market attention, investors should closely monitor news and company announcements.
*   **Risk Management:** The high MDD values and beta suggest that the stock carries significant risk, requiring careful risk management.

**Recommendation:**

Given the mixed signals, a cautious approach is advised. Consider taking advantage of the high cash position recommended by the Hybrid Signal. Investors should carefully weigh the short-term risks against the long-term growth potential before making investment decisions. Long-term investors may find value in TMDX, but should be prepared for potential volatility.
